Attovia Therapeutics, Inc.

Founded in 2023, Attovia Therapeutics, Inc. is a US-based clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases with high unmet need. Built around its ATTOBODY™ platform, Attovia designs next-generation complex and multispecific biologic medicines, with cofounders including Tao Fu, Zaneta Odrowaz, Petter Veiby, Hangjun Zhan, and Yuling Luo. Attovia Therapeutics, Inc.

, based in the US, specializes in developing precision biologics that address immune-mediated diseases, leveraging its ATTOBODY™ platform for innovative multispecific therapies. Attovia Therapeutics, Inc. focuses on advancing treatments for immune-mediated diseases. Attovia's core product offerings center around a new generation of precision biologics that address high unmet needs across immune-mediated diseases.

The company utilizes its proprietary ATTOBODY™ platform, a modular protein design technology that enables the creation of multispecific medicines capable of targeting multiple disease pathways simultaneously. This innovative approach aims to improve therapeutic performance and provides solutions for patients who remain undertreated by existing single-pathway treatments. Attovia's products are positioned to benefit a diverse client base that includes healthcare providers, patients, and pharmaceutical partners, particularly in North America, Europe, and Asia, where there is a significant demand for advanced therapeutic options in the immunology landscape. The focus of Attovia's development efforts is to enhance patient outcomes and expectations regarding treatment efficacy and safety.

Attovia generates revenue through strategic partnerships, collaborations, and potential licensing agreements related to its multi specific biologics. The company's revenue model includes B2B transactions, where it engages with pharmaceutical firms interested in co-developing or licensing its innovative therapies. The structure of these transactions may involve milestone payments and royalties based on product sales, reflecting the value of Attovia’s proprietary technologies and their application in clinical settings. While specific pricing plans for individual products are not disclosed, the revenue framework is designed to capitalize on the successful integration of its ATTOBODY™ platform within broader therapeutic portfolios of its partners, creating a sustainable financial ecosystem as its products progress through development and into the market.

In August 2026, Attovia Therapeutics, Inc. raised USD 289 million in an IPO, selling 17 million shares at USD 17 per share, within the expected USD 15-17 range at the Nasdaq Global Market under the ticker symbol "ATTO", valuing the company at USD 700 million. Following the transaction, Goldman Sachs, Deep Track Capital, Frazier Healthcare Partners, and VenBio retained 5. 7%, 4.

5%, 12. 9%, and an 8. 8% minority stakes, respectively, in the company.